ArticleScientific reports2020
Network and pathway expansion of genetic disease associations identifies successful drug targets.
Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 33 citations in OpenAlex.
- NetPolicy-RL: network-informed offline reinforcement learning for pharmacogenomic drug prioritization.Journal of computer-aided molecular design · 2026Article
- Mapping cross-domain drivers of Alzheimer's disease risk through integrated network analysis.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Bridging genomics and pharmacoepidemiology to expand treatment options for alcohol use disorder.Alcohol, clinical & experimental research · 2026Article
- Genomics of drug target prioritization for complex diseases.Nature reviews. Genetics · 2026Review
- Network pharmacology approach to unravel the neuroprotective potential of natural products: a narrative review.Molecular diversity · 2026Review
- Leveraging large-scale biobanks for therapeutic target discovery.HGG advances · 2026Article
- Bridging Genomics and Pharmacoepidemiology to Expand Treatment Options for Alcohol Use Disorder.medRxiv : the preprint server for health sciences · 2026Article
- A genetics-guided integrative framework for drug repurposing: identifying antihypertensive drugs for type 2 diabetes.NPJ drug discovery · 2026Article
- Integrative Analysis of Vitamin D-Associated Genetic Variants Reveals Cis-Regulatory Architecture and Multigenic Mechanisms Underlying Chronic Disease-Relevant Pathways.Human mutation · 2026Article
- Temporal trends in evidence supporting novel drug target discovery.Nature communications · 2025Article
- Mapping cross-domain drivers of Alzheimer's disease risk through integrated network analysis.bioRxiv : the preprint server for biology · 2025Article
- BioMedGraphica: An All-in-One Platform for Joint Textual Biomedical Prior Knowledge and Numeric Graph Generation.bioRxiv : the preprint server for biology · 2025Article
- Pathway Analysis Interpretation in the Multi-Omic Era.Biotech (Basel (Switzerland)) · 2025Review
- Large-scale multi-omics identifies drug targets for heart failure with reduced and preserved ejection fraction.Nature cardiovascular research · 2025Article
- Leveraging pleiotropy for the improved treatment of psychiatric disorders.Molecular psychiatry · 2025Review
- Shared etiology of Mendelian and complex disease supports drug discovery.BMC medical genomics · 2024Article
- Shared etiology of Mendelian and complex disease supports drug discovery.Research square · 2024Article
- Multi-layered genetic approaches to identify approved drug targets.Cell genomics · 2023Article
- A human proteogenomic-cellular framework identifies KIF5A as a modulator of astrocyte process integrity with relevance to ALS.Communications biology · 2023Article
- Network expansion of genetic associations defines a pleiotropy map of human cell biology.Nature genetics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Genetic evidence of disease association has often been used as a basis for selecting of drug targets for complex common diseases. Likewise, the propagation of genetic evidence through gene or protein interaction networks has been shown to accurately infer novel disease associations at genes for which no direct genetic evidence can be observed. However, an empirical test of the utility of combining these approaches for drug discovery has been lacking. In this study, we examine genetic associations arising from an analysis of 648 UK Biobank GWAS and evaluate whether targets identified as proxies of direct genetic hits are enriched for successful drug targets, as measured by historical clinical trial data. We find that protein networks formed from specific functional linkages such as protein complexes and ligand-receptor pairs are suitable for even naïve guilt-by-association network propagation approaches. In addition, more sophisticated approaches applied to global protein-protein interaction networks and pathway databases, also successfully retrieve targets enriched for clinically successful drug targets. We conclude that network propagation of genetic evidence can be used for drug target identification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.